Latest NRG Therapeutics News & Updates

See the latest news and media coverage for NRG Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

NRG Therapeutics

Clinical-stage neuroscience company developing mitochondrial-targeted therapies for neurodegenerative diseases

nrgtherapeutics.com

Headquarters: Stevenage, United Kingdom
Company type: Private company
Number of employees: 20–50

Last updated Today

Latest news about NRG Therapeutics

In short: NRG Therapeutics launched a first-in-human Phase 1 trial for its lead candidate NRG5051 and raised £50 million in Series B funding.

Company announcements

March 27 NRG Therapeutics

NRG Therapeutics advances NRG5051 in clinical trials

They thank Stevenage Bioscience Catalyst for a video sharing their story. The company focuses on treatments for ALS, MND, and Parkinson's.

January 28 NRG Therapeutics

NRG Therapeutics celebrates featured 2025 £50m Series B

The funding tops UK life sciences deals in BIA report. Investors support NRG5051 for ALS, MND, and Parkinson's.

January 11 NRG Therapeutics

NRG Therapeutics executives attend JPMorgan Healthcare conference

They meet investors, pharma, and collaborators. NRG5051 enters first-in-human trials.

January 8 NRG Therapeutics

NRG Therapeutics doses first participants in NRG5051 Phase 1 trial

The randomized double-blind study assesses safety, tolerability, and pharmacokinetics in healthy volunteers at CHDR in Leiden. It targets ALS/MND and Parkinson’s.

Media coverage

February 22 Pharmaphorum

NRG raises £50m to start trials of Parkinson's, ALS drug

Transmission electron microscope image of a thin section cut through an area of mammalian lung tissue. The high magnification image shows two mitochondria. NRG Therapeutics...

February 14 Pharmaphorum

NRG announces £16m Series A for IND for Parkinson's and ALS

A £16 million Series A financing - led by Omega Funds - has been announced by the innovative neuroscience company NRG Therapeutics Ltd., for the...

January 7 The Manila Times

NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS ...

STEVENAGE, United Kingdom, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. ("NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial...

30 November 2025 PIX11

NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer

STEVENAGE, United Kingdom, Dec. 01, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. ("NRG"), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction...

Never miss news about NRG Therapeutics

Track NRG Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

NRG Therapeutics competitors & trending companies

Browse news for competitors to NRG Therapeutics and other trending companies.